Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000950170-25-058810
Filing Date
2025-04-25
Accepted
2025-04-25 16:40:51
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 21061
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 65710
3 EX-99.2 ck0001669811-ex99_2.pdf EX-99.2 54239
  Complete submission text file 0000950170-25-058810.txt   188123
Mailing Address 2929 7TH STREET, SUITE 105 BERKELEY CA 94710
Business Address 2929 7TH STREET, SUITE 105 BERKELEY CA 94710 510-982-6030
Caribou Biosciences, Inc. (Subject) CIK: 0001619856 (see all company filings)

EIN.: 453728228 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-92726 | Film No.: 25874809
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O CARIBOU BIOSCIENCES, INC. 2929 7TH STREET, SUITE 105 BERKELEY CA 94710
Business Address
Haurwitz Rachel E. (Filed by) CIK: 0001670579 (see all company filings)

Type: SCHEDULE 13D